Progress in Medicinal Chemistry, Volume 46

1st Edition

Hardcover ISBN: 9780444530189
eBook ISBN: 9780080569680
Imprint: Elsevier Science
Published Date: 2nd April 2008
Page Count: 420
210.00 + applicable tax
130.00 + applicable tax
165.00 + applicable tax
187.00 + applicable tax
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

* HIV integrase (discovery of the first-in-class inhibitor drug raltegravir) * 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation) * Nicotinic a7 choline receptor (agonists and positive allosteric modulators) * Bradykinin receptor (new approach to pain therapy) * Histone deacetylase (new drugs for cancer) * 5-HT2c receptor modulators (various CNS indications)

Description

Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, ‘validation’ of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging:

  • HIV integrase (discovery of the first-in-class inhibitor drug raltegravir)
  • 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation)
  • Nicotinic a7 choline receptor (agonists and positive allosteric modulators).
  • Bradykinin receptor (new approach to pain therapy)
  • Histone deacetylase (new drugs for cancer)
  • 5-HT2c receptor modulators (various CNS indications)

Key Features

Presents the latest research in the field of drug discovery Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Readership

Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community


Details

No. of pages:
420
Language:
English
Copyright:
© Elsevier Science 2008
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780080569680
Hardcover ISBN:
9780444530189

Reviews

Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, ‘validation’ of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir) * 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation) * Nicotinic a7 choline receptor (agonists and positive allosteric modulators). * Bradykinin receptor (new approach to pain therapy) * Histone deacetylase (new drugs for cancer) * 5-HT2c receptor modulators (various CNS indications)